Latest news with #AscentagePharmaGroupInternational
Yahoo
25-04-2025
- Business
- Yahoo
Asian Growth Companies With High Insider Ownership
Amidst a backdrop of global trade tensions and economic uncertainties, Asian markets have shown resilience, with China's stock indices advancing on the expectation of increased stimulus measures. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best. Name Insider Ownership Earnings Growth Jiayou International LogisticsLtd (SHSE:603871) 19.3% 25.5% Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) 23.3% 26% AcrelLtd (SZSE:300286) 40% 34.9% Seojin SystemLtd (KOSDAQ:A178320) 32.1% 39.3% Laopu Gold (SEHK:6181) 36.4% 40.2% Global Tax Free (KOSDAQ:A204620) 20.8% 35.1% Oscotec (KOSDAQ:A039200) 21.1% 85.9% BIWIN Storage Technology (SHSE:688525) 17.7% 59.6% Fulin Precision (SZSE:300432) 13.6% 74.7% Suzhou Gyz Electronic TechnologyLtd (SHSE:688260) 16.4% 121.7% Click here to see the full list of 648 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ascentage Pharma Group International, a clinical-stage biotechnology company, focuses on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market cap of HK$17.64 billion. Operations: The company generates revenue from the development and sale of novel small-scale therapies, amounting to CN¥980.65 million. Insider Ownership: 13.5% Revenue Growth Forecast: 22.2% p.a. Ascentage Pharma Group International, a growth-focused biotech company in Asia, showcases high insider ownership and robust R&D capabilities. Recently, its novel drugs lisaftoclax and olverembatinib received significant recognition in the 2025 CSCO Guidelines, enhancing their clinical credibility. Despite past shareholder dilution and share price volatility, Ascentage's revenue is forecast to grow at 22.2% annually, outpacing the Hong Kong market. The company reported CNY 980.65 million in sales for 2024 with a reduced net loss of CNY 405.43 million compared to the previous year. Click to explore a detailed breakdown of our findings in Ascentage Pharma Group International's earnings growth report. Our valuation report here indicates Ascentage Pharma Group International may be overvalued. Simply Wall St Growth Rating: ★★★★★☆ Overview: Wuxi Longsheng Technology Co., Ltd operates in China, specializing in the manufacturing of auto parts, with a market capitalization of CN¥9.13 billion. Operations: The company's revenue is primarily derived from the Auto Parts Industry, contributing CN¥2.37 billion, with an additional CN¥23.18 million coming from the Precision Machining Industry. Insider Ownership: 34.8% Revenue Growth Forecast: 23.7% p.a. Wuxi Longsheng Technology Ltd. demonstrates strong growth potential with its earnings and revenue expected to grow significantly above the market rate at 28.9% and 23.7% per year, respectively. Despite a volatile share price, the company reported robust financial results for 2024, including CNY 2.40 billion in revenue and CNY 224.36 million net income, supported by substantial insider ownership but no recent insider trading activity. A recent share buyback further indicates management's confidence in its future prospects. Dive into the specifics of Wuxi Longsheng TechnologyLtd here with our thorough growth forecast report. Our comprehensive valuation report raises the possibility that Wuxi Longsheng TechnologyLtd is priced higher than what may be justified by its financials. Simply Wall St Growth Rating: ★★★★★☆ Overview: Chroma ATE Inc. is engaged in the design, assembly, manufacturing, sales, repair, and maintenance of software and hardware for computers and peripherals as well as various electronic testing and power supply systems across Taiwan, China, the United States, and other international markets with a market cap of NT$118.42 billion. Operations: The company's revenue segments consist of NT$33.42 billion from the Measuring Instruments Business and NT$1.45 billion from Automated Transport Engineering. Insider Ownership: 14.5% Revenue Growth Forecast: 16.1% p.a. Chroma ATE shows promising growth potential, with earnings forecasted to grow significantly at 20.1% annually, outpacing the Taiwan market. The company trades at a substantial discount of 36.9% below its fair value estimate and was recently added to the FTSE All-World Index. Despite a dividend not fully covered by free cash flows, it reported strong financials for 2024 with TWD 21.60 billion in revenue and TWD 5.26 billion net income, reflecting robust business performance without recent insider trading activity. Take a closer look at Chroma ATE's potential here in our earnings growth report. The analysis detailed in our Chroma ATE valuation report hints at an deflated share price compared to its estimated value. Click through to start exploring the rest of the 645 Fast Growing Asian Companies With High Insider Ownership now. Curious About Other Options? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:6855 SZSE:300680 and TWSE:2360. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
Exploring XD And Two Other High Growth Tech Stocks In Asia
As global markets navigate a landscape of economic uncertainty and mixed signals, with tech stocks in the U.S. recently lagging behind broader indices, investors are increasingly turning their attention to Asia's high-growth tech sector for potential opportunities. In this environment, identifying strong stocks often involves looking at companies that demonstrate resilience and adaptability amid changing economic forecasts and geopolitical risks, as these qualities can be crucial for sustaining growth in dynamic markets like Asia. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 34.71% 33.47% ★★★★★★ Fositek 31.39% 36.95% ★★★★★★ Xi'an NovaStar Tech 30.60% 36.56% ★★★★★★ eWeLLLtd 24.65% 25.30% ★★★★★★ Seojin SystemLtd 31.68% 39.34% ★★★★★★ PharmaResearch 20.19% 26.38% ★★★★★★ giftee 21.13% 67.05% ★★★★★★ JNTC 28.84% 104.08% ★★★★★★ Ascentage Pharma Group International 22.93% 59.90% ★★★★★★ Delton Technology (Guangzhou) 20.25% 29.52% ★★★★★★ Click here to see the full list of 506 stocks from our Asian High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★★☆ Overview: XD Inc. is an investment holding company that focuses on developing, publishing, operating, and distributing mobile and web games in Mainland China and internationally with a market cap of approximately HK$18.24 billion. Operations: The company generates revenue primarily through its Game segment, which brought in CN¥2.43 billion, and the TapTap Platform, contributing CN¥1.43 billion. The focus on both game development and the TapTap distribution platform highlights a dual revenue stream strategy within the gaming industry. XD Inc. has demonstrated a robust trajectory with its revenue expected to surge by 46% to 49% year-over-year, reaching up to RMB 5.04 billion in FY 2024. This growth is complemented by an impressive turnaround from a net loss in FY 2023 to a projected net profit of up to RMB 940 million. The company's commitment to innovation is evident from its substantial investment in R&D, fostering advancements that keep it competitive within Asia's tech landscape. Moreover, XD's earnings are poised for a significant annual increase of approximately 54.6%, outpacing the regional market growth and indicating potential for sustained upward momentum in its financial performance. Navigate through the intricacies of XD with our comprehensive health report here. Explore historical data to track XD's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★★★ Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market cap of approximately HK$12.61 billion. Operations: The company generates revenue primarily through the development and sale of novel small-scale therapies, amounting to CN¥903.03 million. Ascentage Pharma Group International has shown a notable rebound in its financial performance, with sales soaring to CNY 980.65 million in FY 2024 from CNY 221.98 million the previous year, reflecting a remarkable growth trajectory despite the company's net loss narrowing significantly to CNY 405.43 million from CNY 925.64 million. This improvement is underpinned by strategic R&D investments that fuel innovation across its robust pipeline, highlighted by recent breakthroughs like olverembatinib receiving multiple Breakthrough Therapy Designations in China for critical leukemia treatments. These advancements not only underscore Ascentage's commitment to addressing unmet medical needs but also position it well within the high-stakes biotech sector where it continues to push scientific boundaries at major forums like the AACR Annual Meeting. Dive into the specifics of Ascentage Pharma Group International here with our thorough health report. Examine Ascentage Pharma Group International's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Genew Technologies Co., Ltd. is involved in the global research, development, production, and sale of communication and network products with a market capitalization of CN¥5.73 billion. Operations: Genew Technologies Co., Ltd. focuses on the global research, development, production, and sale of communication and network products. The company operates with a market capitalization of CN¥5.73 billion. Genew Technologies Co., Ltd. has pivoted impressively from a net loss to profitability, showcasing a robust annual revenue growth of 30.6% and an even more striking earnings growth of 71%. This performance outpaces the broader Chinese market's average, indicating strong operational efficiency and market acceptance. The shift to profitability is underscored by a recent earnings report for FY 2024, where sales climbed to CNY 950.22 million from CNY 884.41 million the previous year, and net income reached CNY 27.11 million, reversing the prior year's loss of CNY 86.56 million. This financial turnaround is particularly noteworthy in the context of its R&D commitment—integral to its strategic positioning within Asia's competitive tech landscape—highlighting Genew's potential trajectory in influencing regional tech innovation trends. Unlock comprehensive insights into our analysis of Genew TechnologiesLtd stock in this health report. Evaluate Genew TechnologiesLtd's historical performance by accessing our past performance report. Investigate our full lineup of 506 Asian High Growth Tech and AI Stocks right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2400 SEHK:6855 and SHSE:688418. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
